Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Placebo/Peripartum

Placebo for Peripartum

1 paper and 12 clinical trials exploring placebo as a treatment for peripartum.

CompoundComparator / Control

Placebo

Placebo is the most widely referenced comparator in psychedelic clinical research, appearing in over 500 trials. Understanding how placebos are designed, administered, and interpreted is essential to evaluating the evidence base for psychedelic-assisted therapies — and one of the field’s most contested methodological challenges.

Full Placebo profile
IndicationApproximately 15-20% of women experience postpartum depression worldwide.

Peripartum

Peripartum depression, including postpartum depression (PPD), is a significant mental health issue affecting new mothers, characterised by severe mood changes following childbirth. Current research into psychedelic treatments, particularly with compounds like esketamine and psilocybin, shows promising potential to alleviate depressive symptoms in this demographic.

Full Peripartum profile

Academic Research

1 paper
Open Accessindividual

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind, Randomized, Single Ascending Dose Placebo-Controlled Study

This double-blind, randomised, placebo-controlled Phase I study (n=48) evaluates the safety, pharmacokinetics, and psychoactive effects of RE104 (psilocybin analog; Luvesilocin; a prodrug of 4-OH-DiPT) in healthy adults with prior psychedelic experience. RE104 was well tolerated up to 40 mg with no serious adverse events, and plasma levels of its active form correlated with subjective drug effect and mystical experience scores. The compound produced psilocybin-like effects with a shorter duration (3-4 hours), supporting further therapeutic investigation.

Published
July 21, 2025
Journal
Journal of Clinical Psychopharmacology
Authors
Ludbrook, G., Bryson, N., Taylor, B., Hocevar-Trnka, J., Johnson, M. W., Hirman, J., Morrish, G., Alexander, R., Pollack, M.

Clinical Trials

12 trials
Not yet recruitingPhase NA

Effect of a single low-dose dose of esketamine on postpartum depression and quality of recovery in women undergoing cesarean section: a prospective, randomised controlled study

This randomised, parallel-group trial (n=136) is evaluating whether a single low-dose infusion of esketamine after caesarean section can reduce postpartum depressive symptoms and improve recovery in women in China. Participants are allocated to receive intravenous esketamine 0.2 mg/kg over 40 minutes after surgery or an intravenous physiological saline infusion for the same duration as the comparator. The study is interventional and involves adult women aged 18 to 60 years undergoing caesarean delivery. The primary outcome is the Edinburgh Postnatal Depression Scale (EPDS) score, assessed on postpartum day 2 and postpartum day 7. Secondary outcomes include the Obstetric Quality of Recovery-10 (ObsQoR-10) score at 24 and 48 hours postpartum, resting and exercise pain scores measured using a visual analogue scale at 24 hours postpartum, and postpartum length of hospital stay. No phase is specified. The trial is being conducted in China and is sponsored by Dongguan Maternal and Child Health Hospital.

Started
September 1, 2024
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
ChiCTR2400088992
Unknown statusPhase NA

Dose Low Dose Ketamine in Casesarian

Prospective case-control observational study (n=150) comparing single-dose IV ketamine (0.5 mg/kg), ketamine plus midazolam, and saline placebo in patients undergoing caesarean section to evaluate postpartum depression and postoperative outcomes.

Started
June 1, 2024
Type
observational
Randomized
No
Registry ID
NCT06237569
CompletedPhase NA

The Effect of Esketamine on Sleep Disturbance

Randomised, triple-blind, parallel-group trial (n=204) testing a single 0.2 mg/kg IV esketamine injection versus 5 ml 0.9% saline in females undergoing surgical abortion with sleep disturbance.

Started
May 3, 2024
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06388824
CompletedPhase I

A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single, Ascending, Subcutaneous Doses of FT-104 HCl In Healthy Volunteers Safety, Tolerability, and Pharmacokinetics of Subcutaneous FT-104 HCl (SAIL-101)

Double-blind, randomised, placebo-controlled single-ascending subcutaneous dose PK and safety study in healthy volunteers (n≈48; cohorts of 8, 6 active + 2 placebo) of FT-104 HCl (psilocybin formulation).

Started
July 20, 2022
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
ACTRN12622000713796
Unknown statusPhase IV

Effects of Esketamine on Postpartum Depression

Randomised, phase IV trial (n=500) comparing four esketamine concentrations added to postoperative PCIA versus no esketamine for postpartum depression and analgesia after cesarean section.

Started
February 20, 2022
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT05229913
CompletedPhase NA

Esketamine on Postpartum Depression in Cesarean Section Women

Randomised, quadruple-blind, parallel study (n=336) testing prophylactic IV esketamine (0.25 mg/kg) after cord clamp plus esketamine-supplemented PCIA versus saline to prevent postpartum depression after elective cesarean section.

Started
May 1, 2021
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT04860661

Explore further

Search all Placebo papers Search all Peripartum trials Full Placebo profile Full Peripartum profile